PRD Therapeutics, inc. is developing First-in-class oral drugs, PRD001, for lipid metabolic diseases such as Homozygous-familial hypercholesterolemia (HoFH, rare disease), Lysosomal Acid Lipase Deficiency (LAL-D, rare disease), and NASH/NAFLD.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Shirokane, Minato-Ku,tokyo,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.prdtherapeutics.com/
- Keywords
- Show more similar pages.
- HQ
- Minato-ku, Tokyo
Prd Therapeutics, Inc. Questions
Prd Therapeutics, Inc.'s website is https://www.prdtherapeutics.com/
Prd Therapeutics, Inc.'s LinkedIn profile is https://jp.linkedin.com/company/prdtherapeutics
Prd Therapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Prd Therapeutics, Inc..
Prd Therapeutics, Inc.'s industry is
Biotechnology Research
Prd Therapeutics, Inc.'s top competitors are
Hepagene Therapeutics, Inc.,
ピー・シー・エス株式会社,
Azuriris, Inc.,
Rna Nanotherapeutics,
Jd Bioscience,
Metagen Therapeutics, Inc.,
Eligo Bioscience,
Gaudiy Us Inc.,
N.b.medical Inc.,
Gaudiy Financial Labs.
Prd Therapeutics, Inc.'s categories are Biotechnology Research
Prd Therapeutics, Inc.'s founding year is 2021
